S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Omeros Shares Fall After Third-Quarter Loss Widens

Omeros shares dropped in after-hours trading after the clinical-stage biopharmaceutical company reported a third-quarter loss of $57.4 million, wider than the $30.9 million loss recorded a year earlier, as costs and expenses rose.

Omeros Shares Fall After Third-Quarter Loss Widens

The loss was 79 cents a share, compared with 47 cents a share in the year-earlier quarter. Total costs and expenses climbed to $31.4 million from $26.4 million.

Omeros reported product sales of $35.9 million. The company also said sales of Yartemlea, its treatment for stem cell transplant-associated thrombotic microangiopathy, reached $41.8 million in the quarter.

Chief Executive Gregory Demopulos said Yartemlea sales had delivered consecutive quarters of positive operating cash flow.

Omeros fell 9.2% to $15.15 in after-hours trading Monday. The shares had closed down 4.6% at $16.68 and were 2.9% lower for the year.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!